Department of Joint and Sports Medicine, The Affiliated Hospital of Jining Medical University, Jining, Shandong 272029, China.
Department of Pathology, The Second People's Hospital Of Jining, Jining, Shandong 272049, China.
Chin Med J (Engl). 2023 Oct 20;136(20):2412-2420. doi: 10.1097/CM9.0000000000002800. Epub 2023 Aug 31.
Osteosarcoma (OS) is the most common primary malignant bone tumor that more commonly occurs in children and adolescents. The most commonly used treatment for OS is surgery combined with chemotherapy, but the treatment outcomes are typically unsatisfactory. High rates of metastasis and post-treatment recurrence rates are major challenges in the treatment of OS. This underlines the need for studying the in-depth characterization of the pathogenetic mechanisms of OS and development of more effective therapeutic modalities. Previous studies have demonstrated the important role of the bone microenvironment and the regulation of signaling pathways in the occurrence and development of OS. In this review, we discussed the available evidence pertaining to the mechanisms of OS development and identified therapeutic targets for OS. We also summarized the available treatment modalities for OS and identified future priorities for therapeutics research.
骨肉瘤(OS)是最常见的原发性恶性骨肿瘤,更常见于儿童和青少年。OS 的最常用治疗方法是手术联合化疗,但治疗效果通常不理想。高转移率和治疗后复发率是 OS 治疗的主要挑战。这凸显了深入研究 OS 发病机制和开发更有效的治疗方法的必要性。先前的研究表明,骨微环境的重要作用和信号通路的调节在 OS 的发生和发展中起重要作用。在这篇综述中,我们讨论了 OS 发展机制的现有证据,并确定了 OS 的治疗靶点。我们还总结了 OS 的现有治疗方法,并确定了未来治疗研究的重点。
Chin Med J (Engl). 2023-10-20
Exp Biol Med (Maywood). 2022-2
Int J Mol Sci. 2016-4-6
Cancer Med. 2023-3
Int Immunopharmacol. 2023-8
Discov Oncol. 2025-5-26
Front Pharmacol. 2025-1-28
Front Oncol. 2024-10-21
Cancer Med. 2023-3
Int J Med Sci. 2022
Cancer Control. 2022
Ann Transl Med. 2021-9
Cancer Cell Int. 2021-10-18